Skip to main
CABA
CABA logo

Cabaletta Bio (CABA) Stock Forecast & Price Target

Cabaletta Bio (CABA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Cabaletta Bio Inc. has demonstrated positive clinical outcomes in their proprietary CAART cell therapy, with a significant improvement in the Pemphigus Disease Area Index (PDAI) score in a patient, reflecting the therapy's potential effectiveness. The company's advancements in manufacturing processes have led to reduced costs of goods sold (COGS) and enhanced efficiency, which is expected to positively impact gross margins moving forward. Additionally, positive feedback from experts and a strong track record of successful FDA approvals for related CART technologies bolster confidence in Cabaletta's competitive position and the potential for future financial upside.

Bears say

Cabaletta Bio operates in a highly competitive biotechnology landscape, facing significant risks from other companies developing cell therapy platforms and alternative treatment modalities. The company has yet to demonstrate a clear differentiation in efficacy for conditions like myositis and scleroderma, where patient expectations for treatment are high and may not tolerate compromises in effectiveness. Additionally, despite a potential low cost of goods sold (COGS) for its CAR-T therapies, the overall financial position may be adversely affected by the high costs associated with clinical trials and product development, which can hinder profitability and investor confidence.

Cabaletta Bio (CABA) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cabaletta Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cabaletta Bio (CABA) Forecast

Analysts have given Cabaletta Bio (CABA) a Buy based on their latest research and market trends.

According to 8 analysts, Cabaletta Bio (CABA) has a Buy consensus rating as of Nov 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cabaletta Bio (CABA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.